Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA guanine base methylation by alkylation refers to the covalent addition of a methyl group to specific positions on the guanine base within DNA, primarily as a result of exposure to alkylating agents. This process is a form of DNA damage that can have significant biological consequences, including mutagenesis and cytotoxicity. The most common sites for methylation on guanine are N7-guaninie (N7-MeG), and O6-guaninie (O6-MeG). O6-methylguanine mispairs with thymine during replication, resulting in point mutations that contribute significantly to carcinogenesis if not repaired. The primary repair mechanism for O6-MeG lesions involves the enzyme O6-methylguanine-DNA methyltransferase (MGMT, also known as AGT).
DNA alkylation leading to base methylation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA Guanine Base Methylation by Alkylation.